Suppr超能文献

靶向 Mat2A 的新型别构抑制剂抑制 S-腺苷甲硫氨酸的合成。

Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.

机构信息

Oncology Research and Development, Pfizer Inc., San Diego, California, USA.

Oncology Medicinal Chemistry, Pfizer Inc., San Diego, California, USA.

出版信息

Nat Chem Biol. 2017 Jul;13(7):785-792. doi: 10.1038/nchembio.2384. Epub 2017 May 29.

Abstract

S-Adenosyl-L-methionine (SAM) is an enzyme cofactor used in methyl transfer reactions and polyamine biosynthesis. The biosynthesis of SAM from ATP and L-methionine is performed by the methionine adenosyltransferase enzyme family (Mat; EC 2.5.1.6). Human methionine adenosyltransferase 2A (Mat2A), the extrahepatic isoform, is often deregulated in cancer. We identified a Mat2A inhibitor, PF-9366, that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B. Studies exploiting PF-9366 suggested a general mode of Mat2A allosteric regulation. Allosteric binding of PF-9366 or Mat2B altered the Mat2A active site, resulting in increased substrate affinity and decreased enzyme turnover. These data support a model whereby Mat2B functions as an inhibitor of Mat2A activity when methionine or SAM levels are high, yet functions as an activator of Mat2A when methionine or SAM levels are low. The ramification of Mat2A activity modulation in cancer cells is also described.

摘要

S-腺苷-L-蛋氨酸(SAM)是一种酶辅因子,用于甲基转移反应和多胺生物合成。SAM 由三磷酸腺苷(ATP)和 L-蛋氨酸通过蛋氨酸腺苷转移酶酶家族(Mat;EC 2.5.1.6)合成。人类蛋氨酸腺苷转移酶 2A(Mat2A)是一种肝外同工酶,在癌症中经常失调。我们鉴定了一种 Mat2A 抑制剂 PF-9366,它结合 Mat2A 的别构位点,该位点与 Mat2A 调节剂 Mat2B 的结合位点重叠。利用 PF-9366 进行的研究提出了 Mat2A 别构调节的一般模式。PF-9366 或 Mat2B 的别构结合改变了 Mat2A 的活性位点,导致底物亲和力增加和酶周转率降低。这些数据支持这样一种模型,即当蛋氨酸或 SAM 水平较高时,Mat2B 作为 Mat2A 活性的抑制剂起作用,但当蛋氨酸或 SAM 水平较低时,Mat2B 作为 Mat2A 的激活剂起作用。还描述了癌细胞中 Mat2A 活性调节的后果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验